Rahul Singhvi - 08 Oct 2025 Form 4 Insider Report for Kairos Pharma, LTD. (KAPA)

Role
Director
Signature
/s/ Rahul Singhvi
Issuer symbol
KAPA
Transactions as of
08 Oct 2025
Transactions value $
$0
Form type
4
Filing time
26 Nov 2025, 17:26:43 UTC
Previous filing
12 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Singhvi Rahul Director C/O KAIROS PHARMA, LTD., 2355 WESTWOOD BLVD, #139, LOS ANGELES /s/ Rahul Singhvi 26 Nov 2025 0001322731

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KAPA COMMON STOCK Award $0 +19.1K +63.36% $0.00 49.2K 08 Oct 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 19,084 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date.
F2 Consists of 49,204 RSUs which remain subject to vesting.